A Phase 1 interventional study of Niraparib (Tablet for oral suspension) and Dostarlimab in Neoplasms, sponsored by GlaxoSmithKline. Terminated at 2 sites in United Kingdom. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population. This study will be conducted to determine the recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), safety, and efficacy of niraparib in combination with dostarlimab in paediatric participants with recurrent or refractory solid tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 47 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part 1 and Part 2:
For Part 1 only:
ii. For participants with documented BRCAness mutational signature: Existing information on molecular profiling of the participant's tumor tissue must be through a molecular profiling platform such as Individualized Therapy for Relapsed in Childhood (INFORM). Molecular profile information must contain information from whole exome sequencing or whole genome sequencing, including the mutation status of BRCA1 and BRCA 2 and other homologous recombination DNA repair (HRR) pathway genes, mutational signatures including mutational signature 3, and tumor mutational burden (TMB).
iii. NOTE: Participants with recurrent or refractory osteosarcoma, neuroblastoma, adrenocortical carcinoma, Ewing sarcoma, or rhabdomyosarcoma are asked to provide documentation, if available, of the BRCAness mutational signature analysis on DNA sequencing of their tumour.
For Part 2A:
Documentation of BRCAness mutational signature 3 will be requested, but not required, for enrollment.
For Part 2B:
Exclusion Criteria:
For Part 1 and Part 2:
For Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with body weight of ≥ 20 kilogram (kg) and who can swallow niraparib tablets will receive niraparib tablets and dostarlimab.
Drug: Dostarlimab · Drug: Niraparib (Tablet)
Participants who are \<8 years of age will receive niraparib TfOS and dostarlimab.
Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab
Participants with osteosarcoma or neuroblastoma who are ≥8 years of age will receive niraparib TfOS and dostarlimab.
Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab
Participants with osteosarcoma will receive the RP2D of the combination of niraparib and dostarlimab.
Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab · Drug: Niraparib (Tablet)
Participants with neuroblastoma will receive the RP2D of the combination of niraparib and dostarlimab.
Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab · Drug: Niraparib (Tablet)
Niraparib will be administered as TfOS (Tablet for oral suspension)
Dostarlimab will be administered as IV infusion
Niraparib will be administered as tablet
Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)
DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.
Time frame: Up to 42 days
Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)
DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.
Time frame: Up to 42 days
Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events
Thrombocytopenia events were defined as treatment-related toxicities of Grade 3 or Grade 4 thrombocytopenia occurring within the first 42 days of study treatment. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0.
Time frame: Up to 42 days
Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
PFS6 is defined as the percentage of participants without progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death at 6 months from the date of the first dose of study treatment. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
Time frame: At Month 6
Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)
ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using International Neuroblastoma Response Criteria (INRC). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Objective Response Rate (ORR)
ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR using RECIST v1.1 or INRC (for neuroblastoma participants only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Duration of Response (DOR)
DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Niraparib Concentrations
Blood samples were obtained to analyze niraparib concentration levels.
Time frame: 2.5 hours (HR) and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Part 1A and Part 1B: Dostarlimab Concentrations
Blood samples were collected for PK analysis of Dostarlimab.
Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12, 18, 24, 30, 36; End of Treatment (Up to approximately 196 weeks)
Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
Time frame: Up to approximately 196 weeks
Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
The acceptability and palatability for participants who received niraparib tablet or TfOS were evaluated by using a questionnaire.
Time frame: At Week 1 of Cycle 1
Part 2 Safety-run in: Objective Response Rate (ORR)
ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR, using RECIST v1.1 or INRC (neuroblastoma only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Duration of Response (DOR)
DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). It is calculated for participants with a BOR of confirmed CR or PR. If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Disease Control Rate (DCR)
DCR is the percentage of participants achieving a BOR of confirmed CR, PR, or stable disease (SD) by RECIST v1.1 or INRC (neuroblastoma only). Per RECIST v1.1: CR is disappearance of all target lesions and pathological lymph nodes \<10 mm in short axis; PR is ≥30% decrease in lesion diameters from baseline; SD is neither sufficient shrinkage for PR nor sufficient increase for PD. Per INRC: CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Progression-free Survival (PFS)
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 or INRC (in participants with neuroblastoma only) based on Investigator assessment, or death from any cause (whichever occurs first). Per RECISTv1.1: PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Per INRC: PD is \>20% lesion size increase, new lesions, or increased marrow tumor infiltration (\>5%).
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Time frame: Up to approximately 196 weeks
Part 2 Safety-run in: Niraparib Concentrations
Blood samples were obtained to analyze niraparib concentration levels.
Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, Pre-dose on Cycle 1 Week 2 and Pre-dose and 5 HR post-dose on Cycle 2 Week 1
Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1
ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1. CR was defined as disappearance of all target and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
Time frame: Up to approximately 196 weeks
Part 2A: Duration of Response (DOR) by the Investigator Using RECIST v1.1
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by RECIST v1.1 , based on Investigator assessment, or death (whichever occurs first). CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.
Time frame: Up to approximately 196 weeks
Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1
DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) by RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Up to approximately 196 weeks
Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 , based on Investigator assessment, or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
Time frame: Up to approximately 196 weeks
Part 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Time frame: Up to approximately 196 weeks
Part 2A: Niraparib Concentrations
Blood samples were obtained to analyze niraparib concentration levels.
Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Part 2A: Dostarlimab Concentrations
Blood samples were collected for PK analysis of Dostarlimab.
Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4 and 6; End of Treatment (Up to approximately 196 weeks)
Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
Time frame: Up to approximately 196 weeks
Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.
Time frame: At Week 1 of Cycle 1
Part 2B: Duration of Response (DOR) by the Investigator by INRC
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by INRC , based on Investigator assessment, or death (whichever occurs first). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%. PD is \>20% lesion size increase,new lesions or increased tumor infiltration in bone marrow.
Time frame: Up to approximately 196 weeks
Part 2B: Disease Control Rate (DCR) by the Investigator by INRC
DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or SD by INRC. CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.
Time frame: Up to approximately 196 weeks
Part 2B: Progression-free Survival (PFS) by the Investigator by INRC
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by INRC , based on Investigator assessment, or death (whichever occurs first). PD is \>20% lesion size increase, new lesions, or increased tumor infiltration in bone marrow.
Time frame: Up to approximately 196 weeks
Part 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
Time frame: Up to approximately 196 weeks
Part 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
Time frame: Up to approximately 196 weeks
Part 2B: Niraparib Concentrations
Blood samples were obtained to analyze niraparib concentration levels.
Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Part 2B: Dostarlimab Concentrations
Blood samples were collected for PK analysis of Dostarlimab.
Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12 and 18; End of Treatment (Up to approximately 196 weeks)
Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
Time frame: Up to approximately 196 weeks
Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.
Time frame: At Week 1 of Cycle 1
| Milestone | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 11 | 7 | 5 | 3 | 11 | 7 | 3 |
| Dlt-evaluable population | 8 | 6 | 2 | 2 | 0 | 0 | 3 |
| Intent-to-treat (itt) population | 11 | 6 | 5 | 3 | 0 | 0 | 3 |
| Modified intent-to-treat (mitt) population | 0 | 0 | 0 | 0 | 9 | 8 | 0 |
| Pharmacokinetic (pk) population | 11 | 7 | 5 | 3 | 11 | 7 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 7 | 5 | 3 | 11 | 7 | 3 |
| Withdrew: Death | 7 | 3 | 3 | 3 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Reached protocol-defined stopping criteria | 3 | 4 | 2 | 0 | 4 | 4 | 1 |
DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT) | 1 | 1 | 2 | 2 |
DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.
| Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT) | 1 |
Thrombocytopenia events were defined as treatment-related toxicities of Grade 3 or Grade 4 thrombocytopenia occurring within the first 42 days of study treatment. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0.
| Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight- Based Dose) + Dostarlima b 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events | 0 |
PFS6 is defined as the percentage of participants without progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death at 6 months from the date of the first dose of study treatment. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
| Percentage of Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 | 0 (0.0 to 33.6) |
ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using International Neuroblastoma Response Criteria (INRC). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
| Percentage of Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC) | 0 (0.0 to 36.9) |
ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR using RECIST v1.1 or INRC (for neuroblastoma participants only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
| Percentage of Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Objective Response Rate (ORR) | 9 (0.2 to 41.3) | 0 (0.0 to 45.9) | 0 (0.0 to 52.2) | 0 (0.0 to 70.8) |
DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.
| Months | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Duration of Response (DOR) | 37.29 (NA to NA) | — | — | — |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| TEAEs | 11 | 7 | 5 | 3 |
| SAEs | 6 | 2 | 2 | 2 |
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs) | 2 | 5 | 0 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| TEAEs leading to Death | 3 | 1 | 0 | 0 |
| Treatment Discontinuation | 3 | 1 | 1 | 2 |
Blood samples were obtained to analyze niraparib concentration levels.
| nanogram/ millilitre (ng/mL) | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Cycle 1 Week 1, 2.5 HR post-dose | 120.045 ± 198.6774 | 44.300 ± 58.0753 | 83.480 ± 107.4614 | 383.900 ± 413.0918 |
| Cycle 1 Week 1, 7 HR post-dose | 347.889 ± 133.9846 | 254.571 ± 141.7096 | 640.200 ± 449.5850 | 522.500 ± 369.8168 |
| Cycle 1 Week 2, 168 HR post-dose | 419.255 ± 203.6362 | 396.286 ± 276.8006 | 812.000 ± 704.5534 | 887.667 ± 628.3664 |
Blood samples were collected for PK analysis of Dostarlimab.
| milligram/ litre (mg/L) | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Cycle 1 Week 1, Day 1 pre-dose | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| Cycle 1 Week 1, 1 hr post-dose | 58.291 ± 10.7135 | 124.743 ± 30.9267 | 69.720 ± 9.8228 | 129.000 ± 2.6458 |
| Cycle 1 Week 2, 168 hrs post-dose | 21.045 ± 4.5276 | 55.314 ± 10.1568 | 28.660 ± 14.1661 | 55.600 ± 8.2286 |
| Cycle 2 Week 1, 504 hrs post-dose | 12.256 ± 2.1518 | 35.100 ± 11.1095 | 13.240 ± 5.0411 | 43.000 ± 7.4953 |
| Cycle 4 Week 1, Pre-dose | 23.100 ± NA | 81.400 ± NA | — | — |
| Cycle 6 Week 1, Pre-dose | 25.100 ± NA | 103.000 ± NA | — | — |
| Cycle 12 Week 1, Pre-dose | 21.400 ± NA | 58.400 ± NA | — | — |
| Cycle 18 Week 1, Pre-dose | 21.200 ± NA | 60.900 ± NA | — | — |
| Cycle 24 Week 1, Pre-dose | 12.400 ± NA | — | — | — |
| Cycle 30 Week 1, Pre-dose | 33.800 ± NA | — | — | — |
| Cycle 36 Week 1, Pre-dose | 33.500 ± NA | — | — | — |
| End of Treatment, End of Treatment | 16.543 ± 8.6016 | 58.700 ± 47.2811 | 16.507 ± 13.6358 | 46.800 ± 40.5879 |
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab | 0 | 0 | 0 | 0 |
The acceptability and palatability for participants who received niraparib tablet or TfOS were evaluated by using a questionnaire.
| Participants | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|
| Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires | 11 | 7 | 5 | 2 |
ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR, using RECIST v1.1 or INRC (neuroblastoma only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.
| Percentage of Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Objective Response Rate (ORR) | 0 (NA to NA) |
DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). It is calculated for participants with a BOR of confirmed CR or PR. If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.
No measurements were reported for this outcome.
DCR is the percentage of participants achieving a BOR of confirmed CR, PR, or stable disease (SD) by RECIST v1.1 or INRC (neuroblastoma only). Per RECIST v1.1: CR is disappearance of all target lesions and pathological lymph nodes \<10 mm in short axis; PR is ≥30% decrease in lesion diameters from baseline; SD is neither sufficient shrinkage for PR nor sufficient increase for PD. Per INRC: CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.
| Percentage of Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Disease Control Rate (DCR) | 0 (NA to NA) |
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 or INRC (in participants with neuroblastoma only) based on Investigator assessment, or death from any cause (whichever occurs first). Per RECISTv1.1: PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Per INRC: PD is \>20% lesion size increase, new lesions, or increased marrow tumor infiltration (\>5%).
| Months | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Progression-free Survival (PFS) | 1.68 (1.35 to 2) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| TEAEs | 3 |
| SAEs | 2 |
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs) | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
| Participants | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Leading to Death | 0 |
| Treatment Discontinuation | 2 |
Blood samples were obtained to analyze niraparib concentration levels.
| ng/mL | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|
| Cycle 1 Week 1, 2.5 HR post-dose | 109.000 ± 121.7060 |
| Cycle 1 Week 1, 7 HR post-dose | 292.067 ± 225.1404 |
| Cycle 1 Week 2, Pre-dose | 329.200 ± 272.7140 |
| Cycle 2 Week 1, Pre-dose | 338.667 ± 253.1291 |
| Cycle 2 Week 1, 5 HR post-dose | 834.667 ± 612.8428 |
ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1. CR was defined as disappearance of all target and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).
| Percentage of Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1 | 0 (0.0 to 33.6) |
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by RECIST v1.1 , based on Investigator assessment, or death (whichever occurs first). CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.
No measurements were reported for this outcome.
DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) by RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Percentage of Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1 | 0 (0.0 to 33.6) |
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 , based on Investigator assessment, or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
| Months | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1 | 1.2 (0.7 to 2.1) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| TEAEs | 11 |
| SAEs | 4 |
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs) | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
| Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Leading to Death | 0 |
| Treatment Discontinuation | 2 |
Blood samples were obtained to analyze niraparib concentration levels.
| ng/mL | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Cycle 1 Week 1, 2.5 HR post-dose | 217.212 ± 236.5667 |
| Cycle 1 Week 1, 7 HR post-dose | 241.482 ± 143.3515 |
| Cycle 1 Week 2, 168 HR post-dose | 354.100 ± 153.7909 |
Blood samples were collected for PK analysis of Dostarlimab.
| mg/L | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Cycle 1 Week 1, Day 1 pre-dose | 0.000 ± 0.0000 |
| Cycle 1 Week 1, 1 hr post-dose | 135.509 ± 45.2007 |
| Cycle 1 Week 2, 168 hrs post-dose | 65.022 ± 8.6129 |
| Cycle 2 Week 1, 504 hrs post-dose | 45.000 ± 27.4571 |
| Cycle 4 Week 1, Pre-dose | 46.900 ± 23.0517 |
| Cycle 6 Week 1, Pre-dose | 133.000 ± NA |
| End of Treatment, End of Treatment | 74.338 ± 52.2281 |
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
| Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab | 0 |
The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.
| Participants | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) |
|---|---|
| Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires | 11 |
DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by INRC , based on Investigator assessment, or death (whichever occurs first). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%. PD is \>20% lesion size increase,new lesions or increased tumor infiltration in bone marrow.
No measurements were reported for this outcome.
DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or SD by INRC. CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.
| Percentage of Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Disease Control Rate (DCR) by the Investigator by INRC | 38 (8.5 to 75.5) |
PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by INRC , based on Investigator assessment, or death (whichever occurs first). PD is \>20% lesion size increase, new lesions, or increased tumor infiltration in bone marrow.
| Months | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Progression-free Survival (PFS) by the Investigator by INRC | 2.9 (0.5 to 10.2) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| TEAEs | 7 |
| SAEs | 4 |
Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).
| Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs) | 4 |
A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.
| Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Leading to Death | 0 |
| Treatment Discontinuation | 3 |
Blood samples were obtained to analyze niraparib concentration levels.
| ng/mL | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Cycle 1 Week 1, 2.5 HR post-dose | 275.600 ± 330.9424 |
| Cycle 1 Week 1, 7 HR post-dose | 329.571 ± 182.8432 |
| Cycle 1 Week 2, 168 HR post-dose | 700.143 ± 571.6900 |
Blood samples were collected for PK analysis of Dostarlimab.
| mg/L | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Cycle 1 Week 1, Day 1 pre-dose | 0.000 ± 0.0000 |
| Cycle 1 Week 1, 1 hr post-dose | 186.000 ± 117.4748 |
| Cycle 1 Week 2, 168 hrs post-dose | 61.943 ± 13.5405 |
| Cycle 2 Week 1, 504 hrs post-dose | 39.925 ± 13.4205 |
| Cycle 4 Week 1, Pre-dose | 88.500 ± 22.3900 |
| Cycle 6 Week 1, Pre-dose | 173.667 ± 90.4231 |
| Cycle 12 Week 1, Pre-dose | 179.500 ± 24.7487 |
| Cycle 18 Week 1, Pre-dose | 121.000 ± NA |
| End of Treatment, End of Treatment | 93.580 ± 69.6794 |
Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.
| Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab | 0 |
The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.
| Participants | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) |
|---|---|
| Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires | 7 |
Collected over All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | 7/11 (63.6%) | 6/11 (54.5%) | 11/11 (100%) |
| Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | 3/7 (42.9%) | 2/7 (28.6%) | 7/7 (100%) |
| Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | 2/11 (18.2%) | 4/11 (36.4%) | 11/11 (100%) |
| Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | 2/7 (28.6%) | 4/7 (57.1%) | 7/7 (100%) |
| Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/11 | 0/7 | 0/5 | 1/3 | 0/11 | 1/7 | 0/3 |
| Alanine aminotransferase increasedInvestigations | 0/11 | 0/7 | 0/5 | 0/3 | 0/11 | 1/7 | 1/3 |
| HypotoniaNervous system disorders | 0/11 | 0/7 | 0/5 | 1/3 | 0/11 | 0/7 | 0/3 |
| Immune-mediated encephalitisNervous system disorders | 0/11 | 1/7 | 0/5 | 0/3 | 0/11 | 0/7 | 1/3 |
| LethargyNervous system disorders | 0/11 | 0/7 | 0/5 | 1/3 | 0/11 | 0/7 | 0/3 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/11 | 0/7 | 0/5 | 1/3 | 0/11 | 1/7 | 0/3 |
| PyrexiaGeneral disorders | 0/11 | 0/7 | 0/5 | 0/3 | 1/11 | 2/7 | 0/3 |
| Cerebral haemorrhageNervous system disorders | 0/11 | 0/7 | 1/5 | 0/3 | 0/11 | 0/7 | 0/3 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/11 | 0/7 | 1/5 | 0/3 | 0/11 | 0/7 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 0/7 | 0/5 | 0/3 | 0/11 | 1/7 | 0/3 |
| Event | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/11 | 3/7 | 2/5 | 3/3 | 3/11 | 3/7 | 2/3 |
| LeukopeniaBlood and lymphatic system disorders | 0/11 | 2/7 | 2/5 | 0/3 | 2/11 | 0/7 | 3/3 |
| NeutropeniaBlood and lymphatic system disorders | 0/11 | 1/7 | 1/5 | 0/3 | 1/11 | 0/7 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/11 | 0/7 | 2/5 | 1/3 | 1/11 | 3/7 | 2/3 |
| Abdominal painGastrointestinal disorders | 2/11 | 2/7 | 0/5 | 2/3 | 1/11 | 2/7 | 0/3 |
| PainGeneral disorders | 0/11 | 0/7 | 0/5 | 2/3 | 2/11 | 0/7 | 0/3 |
| Alanine aminotransferase increasedInvestigations | 0/11 | 4/7 | 1/5 | 2/3 | 0/11 | 1/7 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 0/11 | 3/7 | 1/5 | 2/3 | 1/11 | 3/7 | 1/3 |
| Platelet count decreasedInvestigations | 2/11 | 1/7 | 1/5 | 2/3 | 1/11 | 2/7 | 0/3 |
| PyrexiaGeneral disorders | 7/11 | 1/7 | 1/5 | 0/3 | 0/11 | 1/7 | 1/3 |
| Age, Continuous(YEARS) | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 13.9 ± 2.84 | 13.7 ± 3.99 | 13.0 ± 3.81 | 6.0 ± 1.00 | 14.3 ± 2.45 | 10.1 ± 2.97 | 14.7 ± 1.53 | 12.9 ± 3.50 |
| Sex: Female, Male(Participants) | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 5 | 3 | 3 | 5 | 3 | 2 | 22 |
| Male | 10 | 2 | 2 | 0 | 6 | 4 | 1 | 25 |
| Race (NIH/OMB)(Participants) | Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg) | Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg | Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg | Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg | Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma) | Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma) | Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 11 | 7 | 5 | 3 | 9 | 5 | 3 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2020 to primary completion in Apr 2025, 54 months.
Results were first posted in Jan 2026, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Dostarlimab